How to Help Your Patients Save Money on Beclomethasone: A Provider's Guide to Savings Programs

Medication affordability is a clinical issue — not just a financial one. Patients who can't afford their Qvar RediHaler will skip doses or stop entirely, leading to poorly controlled asthma, increased exacerbation risk, and preventable emergency department visits. Understanding the savings landscape for Beclomethasone is part of prescribing it effectively.

This guide gives you a concise overview of every cost-reduction tool available for Qvar RediHaler (Beclomethasone Dipropionate HFA) in 2026, segmented by insurance status.

The Cost Problem at a Glance

Retail price (no insurance): $306-$414 per 10.6g inhaler (120 inhalations, 80 mcg); ~$3,600-$5,000/year at twice-daily use

No generic available: Teva device patents don't expire until ~May 2031; no generic competition

Formulary tier: Typically Tier 3 (preferred brand) — brand-name copay applies

For Commercially Insured Patients: Teva Savings Card

The Teva Savings Card for Qvar RediHaler is the most impactful tool for commercially insured patients:

Reduces copay to as low as $15 per fill

Maximum savings: $40 per fill; valid for up to 25 fills

Eligibility restriction: NOT available to patients on Medicare Part D, Medicaid, TRICARE, or any federal/state government insurance program. Commercial insurance (employer-sponsored, marketplace, private) required.

Registration: qvar.com — patient or office staff can register online

Consider having office staff or a care coordinator routinely check Teva Savings Card eligibility for every new Qvar RediHaler prescription. This single step can reduce patient out-of-pocket costs from $40-$75 to $15.

For Uninsured and Underinsured Patients: Teva Cares Foundation PAP

The Teva Cares Foundation Patient Assistance Program provides free Qvar RediHaler to eligible patients:

Patient must be uninsured or underinsured

Income criteria must be met (varies; contact Teva for current thresholds)

Application requires a valid prescription and documentation of income and insurance status

Application is typically submitted by your office on the patient's behalf

Additional PAP resources for uninsured patients: NeedyMeds.org and RxAssist.org maintain comprehensive databases of patient assistance programs for all medications.

For All Patients: GoodRx and Other Discount Cards

GoodRx and SingleCare offer discount coupons that can be used regardless of insurance status (patients must choose between GoodRx and insurance — they cannot use both for the same fill):

GoodRx: As low as ~$196.74 for the most common version; 29% off average retail; accepted at most major pharmacies. No income or insurance requirements.

SingleCare: Accepted at over 35,000 pharmacies; compare prices at multiple locations to find the best deal

For Medicare Patients

Medicare patients cannot use the Teva Savings Card. However, options include:

Medicare Part D covers Qvar; typical copay at Tier 3 is lower than retail price

As of 2026, Medicare Part D has a $2,100 annual out-of-pocket cap under the Inflation Reduction Act — significant protection from catastrophic drug costs

90-day mail-order supply typically reduces per-unit cost

Extra Help/Low Income Subsidy (LIS) program from Medicare may cover most Part D costs for eligible low-income patients

When Cost Savings Aren't Enough: Consider Therapeutic Alternatives

If a patient is ineligible for all programs above and still cannot afford Qvar, therapeutic substitution may be appropriate. Key cost comparison:

Generic Fluticasone Propionate HFA: $30-$80 with GoodRx/SingleCare — dramatically lower than Qvar. Note: requires dose conversion and is not appropriate for patients on CYP3A4 inhibitors.

Generic Budesonide/Formoterol (Breyna): $90-$150 with coupons — appropriate if patient needs ICS/LABA combination

When prescribing a Beclomethasone alternative for cost reasons, document the clinical rationale, calculate the dose equivalence carefully, and submit any required prior authorization for the new medication proactively to minimize therapy gaps.

Formulary and Prior Authorization Strategies

If a plan requires step therapy through generic Fluticasone, document failure or contraindication upfront to avoid back-and-forth

For patients on CYP3A4 inhibitors, document specifically that Beclomethasone is the preferred ICS due to non-CYP3A4 metabolism — this is strong PA justification

For patients with poor inhaler technique, document that the breath-actuated device is clinically indicated

Provider Resources

For tools to help patients find available stock and pricing, visit medfinder for providers. For the clinical shortage briefing, see Beclomethasone shortage update for providers 2026.